Publication | Closed Access

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

InflammationHepatologyMedicineLiver PhysiologyPathologyNon-alcoholic SteatohepatitisLiver DiseaseHepatology FibrosisFatty Liver DiseasePharmacology